July 28, 2026, FMIC organized CME Session and knowledge of viral hepatitis among healthcare professionals. The session, titled “Viral Hepatitis: Prevention, Early Diagnosis & Practical Management," was presented by Dr. Eraj Sarwary.
The program commenced with an introductory presentation by the FMIC Marketing and Communications Team, highlighting the institute's latest healthcare services, recent achievements, and the newly launched Family Hifazat App. The innovative digital platform is designed to enhance patient engagement and improve access to healthcare services through a convenient and user-centered approach.
The session focused on strengthening participants' understanding of the different types of viral hepatitis, including Hepatitis A, B, C, D, and E, their modes of transmission, diagnosis, treatment options, and preventive measures. Participants were also introduced to the interpretation of hepatitis B serology, diagnostic approaches for hepatitis B and C, and the selection of appropriate antiviral therapies.
During the presentation, the significant global burden of viral hepatitis was highlighted. According to the information shared, an estimated 254 million people are living with chronic Hepatitis B, while approximately 50 million people have chronic Hepatitis C worldwide. Viral hepatitis continues to claim around 1.3 million lives annually, with most deaths resulting from cirrhosis and hepatocellular carcinoma (HCC).
The session also covered the natural history and progression of Hepatitis B and Hepatitis C infections, emphasizing the importance of timely diagnosis, monitoring, and treatment to prevent severe liver complications. Special attention was given to individuals who should undergo screening, including pregnant women, blood donors, healthcare workers, individuals with high-risk exposures, and patients with elevated liver enzymes.
Dr. Eraj Sarwary, discussed current treatment options, including the use of antiviral medications for Hepatitis B and direct-acting antiviral (DAA) therapies for Hepatitis C, which have significantly improved treatment outcomes. Recommendations for follow-up care, monitoring of liver disease progression, and strategies to prevent liver cancer were also reviewed.
The session underscored the critical role of prevention through vaccination, safe injection practices, blood safety measures, and early screening of high-risk populations. Key messages emphasized that vaccination remains an effective tool against Hepatitis B, early treatment improves outcomes, and regular monitoring is essential for patients with advanced liver disease.
FMIC remains committed to promoting public health awareness and continuing medical education initiatives that support the prevention, early detection, and effective management of infectious diseases, contributing to improved healthcare outcomes across Afghanistan.
